All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.

The Psoriasis and Psoriatic Arthritis Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Psoriasis and Psoriatic Arthritis Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Psoriasis and Psoriatic Arthritis Hub cannot guarantee the accuracy of translated content. The Psoriasis and Psoriatic Arthritis Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
2023-09-11T07:55:47.000Z

Long-term efficacy of deucravacitinib

Featured
Sep 11, 2023
Share:

Long-term efficacy of deucravacitinib

During the 25th World Congress of Dermatology 2023, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak with Mark Lebwohl, Mount Sinai, New York, U.S. We asked about the long-term efficacy of deucravacitinib.

Lebwohl discusses the data at 112 weeks of continuous deucravacitinib treatment. He also mentions how, by blocking tyrosine kinase 2, deucravacitinib differs from standard therapies, maintaining a high level of efficacy over time.

Newsletter

Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox